期刊文献+

缬沙坦纳米混悬剂的制备及固化 被引量:8

Preparation and Solidification of Valsartan Nano-Suspensions
原文传递
导出
摘要 目的 制备并固化缬沙坦纳米混悬液。方法 采用反溶剂沉淀法和高压匀质法制备缬沙坦纳米混悬液,采用干燥法实现纳米混悬液固化。结果 在处方和工艺筛选基础上,确定反溶剂沉淀法为制备缬沙坦纳米混悬液的最终方法。工艺和处方为:稳定剂为F127,浓度为2 mg·mL-1,药物与稳定剂比为5∶3(W/W),制备温度为10~25℃,搅拌速度为300~600 r·min-1,制得混悬液药物含量为3.3 g·L-1。确定喷雾干燥法为缬沙坦纳米混悬液的干燥固化方法,其工艺为向缬沙坦纳米混悬液中加入缬沙坦2倍量的AEROSIL(R)200,搅拌30 min,充分分散。喷雾干燥参数如下:进口温度110℃,出口温度60~65℃,干燥空气流速0.5 m3·min-1,雾化压力170 kPa,进液速度4 mL·min-1。结论 缬沙坦纳米混悬液粒子平均粒径为30 nm,粒度分布均一;纳米混悬液经过喷雾干燥固体化后得到粉末细腻、疏松、流动性好、溶出度和稳定性良好,适合进一步制备固体制剂。 OBJECTIVE To prepare valsartan nano-suspensions and solidify the suspensions. METHODS Valsartau nano-sus- pensions were prepared by anti-solvent precipitation and high pressure homogenization, and the suspensions were solidified by drying process. RESULTS Anti-solvent precipitation was chosen to prepared valsartan nano-suspensions. Based on the screening formula- tions and technological parameters, the optimal formulation and technological parameter were as following:stabilizer was F127 with the mass concentration of 2 mg · mL - 1, the mass ratio of valsartan to stabilizer was 5: 3, the temperature was 10 - 25 ℃ , the mixing speed was 300 -600 r · min -1 , to obtain 3.3 g · L-1 valsartan nano-suspensions. A spray drying process was selected to solidify the suspen- sions. The optimal mass ratio of AEROSIL (R) 200 to valsartan in the suspensions was 2: 1. After adding AEROSIL(R) 200 to the suspen- sions, the mixture was completely mixed for 30 min. The spray drying process parameters :the inlet temperature was 110 ℃, the outlet tem- perature was 60 -65 ℃, the dry air flow rate was 0. 5 m3 · min -1, the spray pressure was 170 kPa, the feed liquor flow rate was 4 mL· min-1. CONCLUSION The mean diameter of the valsarlan nano-suspensions was 30 nm and the diameter distribution was uniform. The dry valsartan nano-suspensions were fine and puff with good fluidity ,dissoLution and stability, suit to further preparation.
出处 《中国药学杂志》 CAS CSCD 北大核心 2014年第17期1524-1529,共6页 Chinese Pharmaceutical Journal
基金 国家973计划(2009CB930300) 辽宁省教育厅重点实验室项目(LS2010161)
关键词 难溶药物 缬沙坦 纳米粒 纳米混悬剂 poorly soluble drug valsartan nano-particle nano-suspension
  • 相关文献

参考文献14

  • 1FLESCH G, MULLER P, LLOYD P. Absolute bioavailability and phannacokinetics of valsartan, an angiotensin Ⅱ receptor antago- nist, in man [J]. Eur J Clin Pharmacol,1997, 52:115-120.
  • 2PARK Y J, LEE H K, IM Y B, et al. Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion [J]. Arch Pharm Res,2010, 33 (8) :1235-1240.
  • 3YAN Y D, SUNG J H, KIM K K, et al. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes [J]. lnt J Pharm,2012, 422 (1-2) :202-210.
  • 4CAPPELLO B, DI MAIO C, IERVOLINO M, et al. Improvement of solubility and stability of valsartan by hydroxypropyl-\boldbeta-cyclodextrin [J]. J lrtcl Phenom Macro,2006, 54 (3) :289-294.
  • 5DIXIT A R, RAJPUT S J, PATEL S G. Preparation and bioavail- ability assessment of SMEDDS containing valsartan [ J ] . AAPS Pharm Sci Tech,2010, 11 ( 1 ) :314-321.
  • 6LID X, YAN Y D, OH D H, et al. Development of valsartan- loaded gelatin microcapsule without crystal change using hydroxypropylmethylcellulose as a stabilizer [ J ]. Drug Deliv, 2010, 17 (5):322-329.
  • 7YOUN Y S, OH J H, AHN K H, et al. Dissolution rate improve- ment of valsartan by low temperature recrystallization in compressed CO2 : Prevention of excessive agglomeration [ J ]. J Supercritical Fluids ,2011,59 : 117-123.
  • 8RABINOW B E. Nanosuspensions in drug delivery. Nature reviews [J]. Drug Discovery,2004, 3 (9) :785-796.
  • 9NIWA T, MIURA S, DANJO K. Design of dry nanosuspension with highly spontaneous dispersible characteristics to develop solu- bilized formulation for poorly water-soluble drugs [ J ]. Pharm Res, 2011, 28 (9) :2339-2349.
  • 10ABDELWAHED W, DEGOBERT G, STAINMESSE S, et al. Freeze-drying of nanoparticles : Formulation, process and storage considerations [ J]. Adv Drug Deliv Rev, 2006, 58 ( 15 ) : 1688- 713.

同被引文献92

  • 1王懿睿,杜光.难溶性药物纳米混悬剂制备工艺及其应用[J].中国医院药学杂志,2007,27(11):1573-1576. 被引量:16
  • 2李墨,赵秀丽,陈大为,杨云云.注射用葫芦素B自微乳化药物传递系统的处方优化[J].沈阳药科大学学报,2008,25(1):15-19. 被引量:7
  • 3Basniwal R K,Buttar H S,Jain V K,et al. Curcuminnanoparticles: preparation, characterization, andantimicrobial study [J]. J Agric Food Chem, 2011, 59(5):2056-2061.
  • 4Shin M S, Lee Y, Kim H. Method for preparingnanoparticles comprising vitamin K and poly-isopropyl-butyl methacrylate-acrylic acid copolymer withsupercritical fluid using molecular association theory: USPatent, 20080152715 [P]. 2008-06-26.
  • 5Salazar J, Heinzerling O, Muller R H, et al. Processoptimization of a novel production method fornanosuspensions using design of experiments (DoE) [J].IntJPharm, 2011,420(2): 395-403.
  • 6Kipp J E, Doty M J, Rebbeck C L, et al. Compositions ofand method for preparing stable particles in a frozenaqueous matrix: US Patent, 7112340 [P]. 2006-09-26.
  • 7Muller R H, Gohla S, Keck C M. State of the art ofnanocrystals-special features, production, nanotoxicologyaspects and intracellular delivery [J]. Eur J PharmBiopharm, 2011, 78(1): 1-9.
  • 8Lindfors L, Skantze P, Skantze U, et al. Amorphous drugnanosuspensions [J]. Langmuir, 2006,22(3): 906-916.
  • 9Miiller R H, Peters K. Nanosuspensions for theformulation of poorly soluble drugs [J]. Int J Pharm,1998, 160(2): 229-237.
  • 10Yue P F, Li G, Dan J X,et al. Study on formability ofsolid nanosuspensions during solidification II: Novelroles of freezing stress and cryoprotectant property [J]. IntJ Pharm, 2014, 475(1): 35-48.

引证文献8

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部